Replies to post #108867 on Biotech Values

[10nisman]

I have not spoken to them about it, but they certainly don’t need my input to be thinking about it :- ) I would be very surprised if MNTA’s management had not considered—or is now considering—monetizing Lovenox for the right price.

Gotcha. :-) Considering NVS is likely going to be paying MNTA $75 million per quarter for mLovenox for the forseeable future, MNTA should be able to get $1+ billion for that revenue stream. However, if NVS is willing to pay say $1.2 billion (payback being 16 quarters) for MNTA's Lovenox revenue stream why wouldn't NVS just try and buy all of MNTA for $2+ billion ($45-50/sh)?

10nis